Ocugen and Bharat Biotech to Co-Develop BBV152, known as COVAXIN™ candidate outside of the U.S., a Whole-Virion Inactivated COVID-19 Vaccine, for the US Market Learn how different COVID-19 Vaccines work Learn more about phase 3 clinical data from BBV152 View Vaccine Scientific Advisory Board
